RxDoctor Payments Data

Abhishek Singla, MD

Pulmonary Disease · Cincinnati, OHNPI 1417237538

Payments from drug & device makers

$593in general payments, 2019–2025

Across 25 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$225
  • Mallinckrodt Hospital Products Inc.$122
  • AstraZeneca$98
  • Insmed, Inc.$56
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$29
  • Johnson & Johnson$25
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$49383%
  • Education$10017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$593 in reported general payments places this provider in the 30th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$72,664
Medicare patients
229
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate69$888,597
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$31,268
Breo ElliptaFluticasone/Vilanterol54$23,157
Mycophenolate Mofetil133$18,768
Incruse ElliptaUmeclidinium Bromide34$13,569
Spiriva RespimatTiotropium Bromide21$10,996
SymbicortBudesonide/Formoterol Fumarate33$8,567
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,266
Advair HfaFluticasone Propion/Salmeterol14$4,705
Albuterol Sulfate HfaAlbuterol Sulfate83$2,051
Advair DiskusFluticasone Propion/Salmeterol13$2,048
Azathioprine26$1,737
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,195
Prednisone155$1,150
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$1,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$225$74,260140 claims
AstraZenecaSymbicort$98$8,56733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →